文献速递心律失常血脂与心血管预防

设备检测心房颤动后抗凝处方的实践差异与结局

Practice Variation in Anticoagulation Prescription and Outcomes After Device-Detected Atrial Fibrillation.
PubMed 文献 · Circulation · 2019-03-17

该回顾性队列研究基于退伍军人健康管理局2011至2014年远程监测数据,纳入CHA2DS2-VASc评分≥2且无卒中或抗凝史的植入心脏电子设备患者。发现设备检测心房颤动后90天内口服抗凝启动率低且随房颤负荷增加仅轻度升高,站点间差异大;调整模型中口服抗凝与>24小时房颤负荷者卒中风险降低相关。

要点

  • 设备检测房颤常见,但90天内口服抗凝启动率低,即使>24小时房颤也仅27%。
  • 52个站点间口服抗凝处方率差异大(中位16%,范围3%-67%)。
  • 调整模型中,>24小时设备检测房颤后口服抗凝与卒中风险降低相关(HR 0.28)。

核心结论

  • 设备检测心房颤动后口服抗凝启动率低且站点间实践差异大,>24小时房颤负荷者口服抗凝与卒中风险降低关联最强。
  • 观察性发现需随机试验确认。

研究设计与样本

  • 回顾性队列研究,使用退伍军人健康管理局2011至2014年数据,链接远程监测日水平房颤负荷。
  • 纳入植入心脏电子设备、CHA2DS2-VASc评分≥2且前2年无卒中或口服抗凝的患者。
  • 分析新设备检测房颤后90天内口服抗凝处方比例及站点差异,用多变量Cox回归评估口服抗凝与卒中关联。

主要发现

  • 房颤>1小时者1712例,72±10岁,女性1.5%,CHA2DS2-VASc评分4.0±1.4,HAS-BLED评分2.6±1.1。
  • 口服抗凝处方比例随房颤负荷增加:≥6分钟13%、>1小时16%、>6小时21%、>24小时27%。
  • 52个站点(1329例患者)房颤>1小时后口服抗凝处方中位16%,范围3%-67%,中位比值比1.56(95%可信区间1.49-1.71)。
  • 调整模型中,房颤>24小时后口服抗凝与卒中风险降低相关(风险比0.28;95%CI 0.10-0.81;P=0.02),倾向评分调整模型在房颤至少6分钟时显著。

关键数值与推荐

  • 设备检测房颤>6分钟至>24小时各阈值下90天内口服抗凝处方比例分别为13%、16%、21%、27%。
  • 站点间口服抗凝处方中位比值比1.56(95%可信区间1.49-1.71)。
  • 房颤>24小时后口服抗凝与卒中风险降低相关(风险比0.28;95%CI 0.10-0.81;P=0.02)。

临床怎么用

  • 设备检测房颤后应评估口服抗凝适应证,尤其房颤持续>24小时者。
  • 需注意站点间实践差异大,可考虑标准化抗凝决策流程。
  • 观察性结果提示口服抗凝可能降低卒中风险,但需随机试验证实。

局限性

  • 回顾性观察性设计,存在残余混杂可能。
  • 研究人群以退伍军人为主,女性仅1.5%,外推性受限。
  • 随机试验 needed 以确认观察性发现。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Device-detected atrial fibrillation (AF) is associated with increased risk of stroke; however, there are no clearly defined thresholds of AF burden at which to initiate oral anticoagulation (OAC). We sought to describe OAC prescription practice variation in response to new device-detected AF and the association with outcomes. METHODS: We performed a retrospective cohort study using data from the Veterans Health Administration linked to remote monitoring data that included day-level AF burden. We included patients with cardiac implantable electronic devices and remote monitoring from 2011 to 2014, CHA2DS2-VASc score ≥2, and no prior stroke or OAC receipt in the preceding 2 years. We determined the proportion of patients prescribed OAC within 90 days after new device-detected AF across a range of AF thresholds (≥6 minutes to >24 hours) and examined site variation in OAC prescription. We used multivariable Cox proportional hazards regressions to determine the association of OAC prescription with stroke by device-detected AF burden. RESULTS: Among 10 212 patients with cardiac implantable electronic devices, 4570 (45%), 3969 (39%), 3263 (32%), and 2469 (24%) had device-detected AF >6 minutes, >1 hour, >6 hours, and >24 hours, respectively. For device-detected AF >1 hour, 1712 patients met inclusion criteria (72±10 years; 1.5% female; CHA2DS2-VASc score 4.0±1.4; HAS-BLED score 2.6±1.1). The proportion receiving OAC varied based on device-detected AF burden (≥6 minutes: 272/2101 [13%]; >1 hour: 273/1712 [16%]; >6 hours: 263/1279 [21%]; >24 hours: 224/818 [27%]). Across 52 sites (N=1329 patients), there was substantial site-level variation in OAC prescription after device-detected AF >1 hour (median, 16%; range, 3%-67%; median odds ratio, 1.56 [95% credible interval, 1.49-1.71]). In adjusted models, OAC prescription after device-detected AF >24 hours was associated with reduced stroke risk (hazard ratio, 0.28; 95% CI, 0.10-0.81; P=0.02), although the propensity-adjusted model was significant when AF lasted at least 6 minutes. CONCLUSIONS: Among veterans with cardiac implantable electronic devices, device-detected AF is common. There is large practice variation in 90-day OAC initiation after new device-detected AF, with low rates of treatment overall, even for episodes that last >24 hours. The strongest association of OAC with reduction in stroke was observed after device-detected AF >24 hours. Randomized trials are needed to confirm these observational findings.

来源:Circulation,查看原文。版权归原作者所有。

引用

  1. Perino AC, Fan J, Askari M, et al. Practice Variation in Anticoagulation Prescription and Outcomes After Device-Detected Atrial Fibrillation. Circulation. 2019. PMID: 30880434. doi:10.1161/CIRCULATIONAHA.118.038988

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。